Sign In
Buy OBSV
$0.102
+0 (+0%)
At Close: Jun 21, 2023
ObsEva appoints Brian O'Callaghan as Chief Executive Officer
01:00am, Monday, 09'th Nov 2020ObsEva SA hosts live symposium and presents oral communication at the SEUD Online Week November 3 - 6, 2020
01:00am, Monday, 02'nd Nov 2020
Geneva, Switzerland and Boston, MA – 2 November, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve
ObsEva SA to present at the Wedbush PacGrow Healthcare Virtual Conference, August 11 – 12, 2020
05:00am, Friday, 07'th Aug 2020
Geneva, Switzerland and Boston, MA – August 7, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s rep
ObsEva Announces Second Quarter 2020 Financial Results and Business Update
05:00am, Thursday, 06'th Aug 2020
* Primary endpoint successfully met in Phase 3 PRIMROSE 1 trial of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids * Phase 3 data from PRIMROSE 2 trial demonstrated s
ObsEva SA Awarded Clinical Science Award for Oral Presentation at ESHRE Virtual 36th Annual Meeting, July 2020
05:00am, Wednesday, 15'th Jul 2020
Geneva, Switzerland and Boston, MA – July 15, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to.
The Week Ahead In Biotech: Endo, Eagle Pharma FDA Decisions, ObsEva Late-Stage Readouts In Focus
12:08pm, Monday, 06'th Jul 2020
Biotech stocks rebounded in the holiday-shortened week ending July 2 as investors reacted to pending clinical trial readouts and the news flow surrounding COVID-19 vaccine and treatment development. A
PRIMROSE 1 achieved statistically significant and clinically meaningful results across primary and key secondary endpoints at week 24 PRIMROSE 2 results demonstrate.
ObsEva SA to present at ESHRE Virtual 36th Annual Meeting, July 5-8, 2020
05:00am, Friday, 03'rd Jul 2020
Geneva, Switzerland and Boston, MA – July 3, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to.
ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA
05:00am, Wednesday, 01'st Jul 2020
July 1, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN - a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that comp
Geneva, Switzerland and Boston, MA – June 29, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel.
Is ObsEva SA (OBSV) A Good Stock To Buy?
02:40am, Monday, 22'nd Jun 2020
In this article we will check out the progression of hedge fund sentiment towards ObsEva SA (NASDAQ:OBSV) and determine whether it is a good investment right now. We at Insider Monkey like to examine
ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2020 Annual General Meeting held on June 9, 2020
08:01pm, Tuesday, 09'th Jun 2020
June 9, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that comp
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peak (Biotech Stocks Hitting 52-week Highs June 3) * Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) * BioMari
ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis
05:00am, Thursday, 04'th Jun 2020
ObsEva SA (OBSV) (SIX:OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported publication in the journal Fertility an
ObsEva SA to present at the Jefferies Virtual Healthcare Conference June 3rd, 2020
05:00am, Friday, 29'th May 2020
Geneva, Switzerland and Boston, MA – May 29, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to.
